Acute Kidney Injury: Pathophysiology, Classification, and Management

Acute kidney injury (AKI) represents a rapid deterioration in kidney function occurring over hours to days, characterized by accumulation of nitrogenous waste products and disruption of fluid, electrolyte, and acid-base homeostasis. The condition affects approximately 20% of hospitalized patients and carries significant morbidity and mortality.

KDIGO Criteria for AKI Diagnosis:

• Increase in serum creatinine ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours
• Increase in serum creatinine ≥1.5 times baseline within 7 days
• Urine volume <0.5 mL/kg/h for 6 hours

AKI Staging (KDIGO):

The traditional classification system divides AKI into three categories based on anatomical location: prerenal (decreased renal perfusion), intrinsic (direct kidney damage), and postrenal (urinary tract obstruction). This classification guides both diagnostic approach and therapeutic interventions, making it essential for clinical practice.

Early recognition is crucial as prompt intervention can prevent progression to chronic kidney disease and reduce mortality. The condition's reversibility depends largely on the underlying cause, duration of injury, and timeliness of treatment. Understanding the pathophysiological mechanisms underlying each category enables targeted therapeutic approaches and improved patient outcomes.

Prerenal AKI results from reduced renal perfusion pressure, leading to decreased glomerular filtration rate (GFR) without intrinsic kidney damage. The kidneys attempt to preserve function through autoregulatory mechanisms, including activation of the renin-angiotensin-aldosterone system (RAAS) and release of antidiuretic hormone (ADH).

Pathophysiological Mechanisms:

• Decreased effective arterial blood volume
• Impaired renal autoregulation (normally maintains GFR when MAP 80-180 mmHg)
• Activation of neurohormonal systems (RAAS, sympathetic nervous system)
• Increased sodium and water retention
• Concentrated urine production to preserve volume

Common Causes of Prerenal AKI:

Volume Depletion:

• Hemorrhage, dehydration, burns
• Gastrointestinal losses (vomiting, diarrhea)
• Third-spacing (sepsis, cirrhosis, nephrotic syndrome)
• Diuretic overuse

Decreased Cardiac Output:

• Heart failure, cardiogenic shock
• Massive pulmonary embolism
• Cardiac tamponade

Altered Renal Hemodynamics:

• ACE inhibitors/ARBs (especially with bilateral renal artery stenosis)
• NSAIDs (inhibit prostaglandin-mediated vasodilation)
• Calcineurin inhibitors (cyclosporine, tacrolimus)
• Contrast-induced nephropathy

Hepatorenal Syndrome: A specific form of prerenal AKI occurring in patients with advanced liver disease, characterized by intense renal vasoconstriction despite systemic vasodilation. Type 1 is rapidly progressive with doubling of creatinine >2.5 mg/dL within 2 weeks, while Type 2 shows gradual progression.

The key characteristic of prerenal AKI is its potential reversibility with restoration of adequate renal perfusion. However, prolonged prerenal conditions can progress to acute tubular necrosis (intrinsic AKI), emphasizing the importance of early recognition and intervention.

Intrinsic AKI involves direct damage to kidney parenchyma, affecting glomeruli, tubules, interstitium, or vasculature. Unlike prerenal AKI, intrinsic injury typically requires time for recovery even after removing the inciting factor.

Classification by Anatomical Location:

1. Glomerular (5-10% of intrinsic AKI):

• Rapidly progressive glomerulonephritis (RPGN)
• Post-infectious glomerulonephritis
• Anti-GBM disease (Goodpasture syndrome)
• ANCA-associated vasculitis
• Lupus nephritis

2. Tubular (85% of intrinsic AKI):

Acute Tubular Necrosis (ATN):

• Ischemic ATN: Prolonged prerenal conditions, surgery, sepsis
• Nephrotoxic ATN: Aminoglycosides, contrast agents, chemotherapy, rhabdomyolysis

Pathophysiology of ATN:

• Loss of tubular cell polarity and tight junctions
• Cast formation obstructing tubular lumens
• Backleak of filtrate through damaged epithelium
• Reduced GFR due to afferent arteriole vasoconstriction

3. Interstitial (10-15% of intrinsic AKI):

• Acute interstitial nephritis (AIN)
• Drug-induced: NSAIDs, antibiotics, PPIs, diuretics
• Infection-related: Legionella, Streptococcus
• Systemic diseases: Sarcoidosis, SLE

4. Vascular (<5% of intrinsic AKI):

• Renal artery occlusion (thrombosis, embolism)
• Renal vein thrombosis
• Malignant hypertension
• Thrombotic microangiopathy (TTP/HUS)

Recovery Phases of ATN:

1. Initiation Phase: Initial injury (hours to days)
2. Maintenance Phase: Established AKI with stable, reduced GFR (1-3 weeks)
3. Recovery Phase: Gradual improvement in kidney function (weeks to months)

The oliguric phase typically lasts 1-3 weeks, followed by a polyuric phase as tubular function recovers but concentrating ability remains impaired. Complete recovery may take months, and some patients develop chronic kidney disease.

Postrenal AKI results from urinary tract obstruction that must be bilateral (or unilateral in a single functioning kidney) to cause significant AKI. Early recognition and relief of obstruction are crucial for preserving kidney function.

Anatomical Locations and Causes:

Upper Urinary Tract Obstruction:

• Nephrolithiasis (calcium oxalate, uric acid, struvite stones)
• Ureteropelvic junction obstruction
• Retroperitoneal fibrosis
• Malignancy (cervical, prostate, bladder, lymphoma)
• Blood clots, fungal balls

Lower Urinary Tract Obstruction:

• Benign prostatic hyperplasia (most common in elderly men)
• Prostate cancer
• Bladder neck contracture
• Urethral strictures
• Neurogenic bladder
• Bladder stones
• Blood clots

Pathophysiology of Obstructive Nephropathy:

1. Acute Phase (0-24 hours):

   • Increased intratubular pressure
   • Initial rise in renal blood flow
   • Maintained or slightly reduced GFR

2. Subacute Phase (24 hours-2 weeks):

   • Progressive decline in renal blood flow
   • Decreased GFR
   • Tubular atrophy begins

3. Chronic Phase (>2 weeks):

   • Irreversible nephron loss
   • Interstitial fibrosis
   • Chronic kidney disease development

Clinical Presentation:

• Anuria or severe oliguria (sudden onset suggests obstruction)
• Flank pain (acute ureteral obstruction)
• Suprapubic pain (bladder outlet obstruction)
• Alternating oliguria and polyuria
• Nausea, vomiting, uremic symptoms

Post-Obstructive Diuresis: After relief of chronic obstruction, patients may develop massive diuresis due to:

• Osmotic diuresis from retained urea
• Impaired tubular concentrating ability
• Suppressed ADH response
• Natriuretic factors accumulation

This requires careful monitoring and fluid replacement to prevent volume depletion and electrolyte imbalances.

Accurate diagnosis of AKI requires systematic evaluation of clinical history, physical examination, laboratory studies, and imaging. The diagnostic approach aims to classify AKI type and identify reversible causes.

Laboratory Studies:

Serum Chemistry:

• Creatinine and BUN (BUN:creatinine ratio interpretation)
• Electrolytes (Na⁺, K⁺, Cl⁻, HCO₃⁻)
• Calcium, phosphate, magnesium
• Complete blood count
• Liver function tests

BUN:Creatinine Ratio Interpretation:

Urinalysis and Microscopy:

Prerenal AKI:

• Specific gravity >1.020
• Osmolality >500 mOsm/kg
• Few or no cells/casts
• Bland sediment

Intrinsic AKI:

Acute Tubular Necrosis:

• Specific gravity <1.010
• Muddy brown granular casts
• Renal tubular epithelial cells
• Osmolality <300 mOsm/kg

Glomerulonephritis:

• Red blood cell casts (pathognomonic)
• Dysmorphic RBCs
• Proteinuria (often nephrotic range)
• White blood cell casts

Acute Interstitial Nephritis:

• White blood cell casts
• Eosinophiluria (>1% of urinary WBCs)
• Sterile pyuria
• Mild proteinuria

Postrenal AKI:

• Variable findings
• May be normal early in obstruction
• Crystals may suggest stone disease
• Hematuria common

Additional Diagnostic Tests:

• Urine protein electrophoresis
• Complement levels (C3, C4)
• Antinuclear antibodies (ANA)
• ANCA, anti-GBM antibodies
• Hepatitis B/C serology
• Blood cultures, lactate
• Creatine kinase (rhabdomyolysis)

Imaging Studies:

• Renal ultrasound (hydronephrosis, kidney size)
• Non-contrast CT (stones, obstruction)
• Doppler ultrasound (renal blood flow)
• CT angiography (renal artery stenosis)
• Nuclear medicine scans (differential function)

The fractional excretion of sodium (FENa) is a crucial diagnostic tool for differentiating prerenal from intrinsic AKI. It measures the percentage of filtered sodium that is excreted in urine, reflecting tubular sodium handling capacity.

FENa Calculation: FENa = [(Urine Na⁺ × Serum Creatinine) / (Serum Na⁺ × Urine Creatinine)] × 100

FENa Interpretation:

Limitations of FENa:

• Recent diuretic use (use FEUrea instead)
• Chronic kidney disease (baseline tubular dysfunction)
• Sepsis (may have low FENa despite intrinsic injury)
• Contrast nephropathy (may present with low FENa initially)
• Glomerulonephritis (variable FENa)

Fractional Excretion of Urea (FEUrea): Useful when diuretics have been administered: FEUrea = [(Urine Urea × Serum Creatinine) / (Serum Urea × Urine Creatinine)] × 100

• <35%: Suggests prerenal AKI

• 50%: Suggests intrinsic AKI

Diagnostic Algorithm for AKI:

AKI Suspected (↑Creatinine, ↓Urine Output) │ ├── History & Physical Exam │ ├── Volume status assessment │ ├── Medication review │ └── Obstruction symptoms │ ├── Laboratory Studies │ ├── Urinalysis + microscopy │ ├── FENa (or FEUrea if diuretics) │ └── Additional tests as indicated │ ├── Imaging │ └── Renal ultrasound │ └── Classification ├── Prerenal: FENa <1%, concentrated urine ├── Intrinsic: FENa >2%, abnormal sediment └── Postrenal: Hydronephrosis on imaging

Additional Biomarkers: Emerging biomarkers for early AKI detection:

• Neutrophil gelatinase-associated lipocalin (NGAL)
• Kidney injury molecule-1 (KIM-1)
• Cystatin C
• Interleukin-18 (IL-18)

These biomarkers may detect kidney injury before creatinine elevation but are not yet widely used in clinical practice.

AKI management focuses on treating underlying causes, preventing further injury, and providing supportive care while awaiting kidney function recovery. Treatment strategies vary based on AKI classification and severity.

General Management Principles:

1. Immediate Assessment and Stabilization:

• ABC assessment (Airway, Breathing, Circulation)
• Hemodynamic stabilization
• Electrolyte management (especially hyperkalemia)
• Acid-base balance correction
• Volume status optimization

2. Identify and Treat Underlying Causes:

• Discontinue nephrotoxic medications
• Optimize hemodynamics
• Relieve obstruction
• Treat specific diseases (glomerulonephritis, vasculitis)

Prerenal AKI Management:

Prerenal AKI Identified │ ├── Volume Depletion │ ├── IV fluid resuscitation │ │ ├── Crystalloids (NS or LR) │ │ └── Monitor response (UOP, Cr) │ └── Avoid nephrotoxins │ ├── Cardiogenic │ ├── Optimize cardiac output │ ├── Diuretics if volume overloaded │ └── Inotropic support if needed │ └── Hepatorenal Syndrome ├── Discontinue diuretics ├── Albumin + vasoconstrictors └── Consider TIPS or transplant

Intrinsic AKI Management:

Acute Tubular Necrosis:

• Supportive care
• Maintain euvolemia
• Avoid further nephrotoxins
• Nutritional support
• Monitor for complications

Glomerulonephritis:

• Immunosuppressive therapy
• Plasmapheresis (anti-GBM, ANCA vasculitis)
• Steroids ± cytotoxic agents
• Blood pressure control

Acute Interstitial Nephritis:

• Discontinue offending agent
• Corticosteroids (controversial)
• Supportive care

Postrenal AKI Management:

Obstruction Identified │ ├── Upper Tract │ ├── Nephrostomy tube │ ├── Ureteral stent │ └── Treat underlying cause │ ├── Lower Tract │ ├── Foley catheter │ ├── Suprapubic catheter │ └── Address obstruction │ └── Post-Relief Care ├── Monitor for post-obstructive diuresis ├── Fluid/electrolyte replacement └── Follow kidney function

Renal Replacement Therapy (RRT) Indications:

• Absolute indications (AEIOU):

  • Acidosis (severe metabolic, pH <7.1)
  • Electrolytes (hyperkalemia >6.5 mEq/L)
  • Intoxications (methanol, ethylene glycol)
  • Overload (pulmonary edema)
  • Uremia (pericarditis, encephalopathy)

• Relative indications:

  • Oliguria/anuria >72 hours
  • Creatinine >8-10 mg/dL
  • BUN >100 mg/dL

RRT Modalities:

• Intermittent hemodialysis: Hemodynamically stable patients
• Continuous renal replacement therapy (CRRT): Hemodynamically unstable
• Peritoneal dialysis: Limited use in AKI

AKI is associated with significant morbidity and mortality, requiring vigilant monitoring for complications and long-term sequelae. Understanding prognostic factors and prevention strategies is essential for optimal patient outcomes.

Acute Complications:

1. Electrolyte Imbalances:

• Hyperkalemia: Most life-threatening, requires immediate treatment
• Hyperphosphatemia: Binds calcium, causes secondary hyperparathyroidism
• Hyponatremia/Hypernatremia: From impaired water handling
• Hypocalcemia: Secondary to hyperphosphatemia and decreased calcitriol
• Hypermagnesemia: From reduced excretion

2. Acid-Base Disorders:

• Metabolic acidosis with anion gap (uremic acids)
• Respiratory compensation may be inadequate
• Severe acidosis (pH <7.1) requires RRT

3. Volume Overload:

• Pulmonary edema
• Peripheral edema
• Hypertension
• Heart failure exacerbation

4. Uremic Complications:

• Pericarditis (friction rub, chest pain)
• Encephalopathy (confusion, seizures)
• Bleeding tendency (platelet dysfunction)
• Nausea, vomiting, decreased appetite

5. Infection Risk:

• Increased susceptibility to infections
• Catheter-related bloodstream infections
• Pneumonia, urinary tract infections

Long-term Consequences:

Chronic Kidney Disease Development:

• Risk factors: Severity of AKI, duration, pre-existing CKD
• AKI-CKD progression mechanisms:
  • Incomplete tubular recovery
  • Interstitial fibrosis
  • Glomerular sclerosis
  • Vascular changes

Cardiovascular Complications:

• Increased risk of myocardial infarction
• Heart failure
• Stroke
• Mechanisms: Inflammation, mineral bone disorders, hypertension

Prognostic Factors:

Poor Prognosis Indicators:

• Advanced age
• Multiple organ failure
• Sepsis
• Severe AKI (Stage 3)
• Need for RRT
• Oliguria >3 days
• Pre-existing CKD

Recovery Predictors:

• Young age
• Single organ involvement
• Prerenal or postrenal etiology
• Early intervention
• Absence of comorbidities

Prevention Strategies:

High-Risk Patient Identification:

• Pre-existing CKD
• Diabetes mellitus
• Heart failure
• Advanced age
• Sepsis, shock
• Major surgery

Preventive Measures:

1. Nephrotoxin Avoidance:

   • Minimize contrast exposure
   • Adjust drug dosing for kidney function
   • Avoid NSAIDs in high-risk patients
   • Monitor aminoglycoside levels

2. Hemodynamic Optimization:

   • Maintain adequate perfusion pressure
   • Avoid hypotension during surgery
   • Optimize volume status

3. Specific Interventions:

   • N-acetylcysteine for contrast nephropathy (controversial)
   • Isotonic saline hydration before procedures
   • Perioperative care protocols

Follow-up and Monitoring:

• Serial creatinine monitoring
• Proteinuria assessment
• Blood pressure control
• Cardiovascular risk factor modification
• CKD progression monitoring